Sign in

    Gonzalo Artiach

    Senior Equity Analyst at Danske Bank

    Gonzalo Artiach is a Senior Equity Analyst at Danske Bank, specializing in Nordic energy and renewables, with a primary focus on utility and renewable energy companies in the region. His coverage includes major players such as Ørsted, Vestas, and Fortum, where he provides investment insight and detailed equity research. Artiach began his career in financial analysis more than a decade ago and joined Danske Bank as an equity analyst after previously working in related roles within the European financial sector. He holds advanced credentials in financial analysis and is recognized for in-depth sector expertise, though specific success rates and rankings are not publicly available.

    Gonzalo Artiach's questions to ASTRAZENECA (AZN) leadership

    Gonzalo Artiach's questions to ASTRAZENECA (AZN) leadership • Q2 2025

    Question

    Gonzalo Artiach of Danske Bank inquired about AstraZeneca's confidence in tozorakimab for COPD following mixed competitor data in the IL-33 space, and asked for details on the onselimab patient subgroup that showed positive results.

    Answer

    EVP of Biopharmaceuticals R&D, Sharon Barr, expressed confidence in tozorakimab, highlighting its differentiated profile that inhibits signaling through both ST2 and RAGE-EGFR pathways, which is important for COPD. CEO of Alexion, Marc Dunoyer, described the onselimab subgroup as a 'sizable minority' that saw a 'very meaningful' clinical benefit, but declined to provide further details ahead of a formal data presentation.

    Ask Fintool Equity Research AI